Jump to content

KannaLife: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
GreenC bot (talk | contribs)
Bots
2,555,703 edits
 
(46 intermediate revisions by 29 users not shown)
Line 1: Line 1:
{{Short description|Pharmaceutical and medical company}}
{{Infobox company
{{Infobox company
|name = KannaLife Sciences Inc.
|name = Kannalife Sciences Inc.
|logo = [[File:Kannalife-logo.jpg|250px|Corporate logo]]
|logo = [[File:Kannalife-logo.jpg|250px|Corporate logo]]
|type = [[Private company|Private]]
|type = Private (Subsidiary)
|slogan =
|company_slogan =
|foundation = 2010
|foundation = 2010
|founders = Dean Petkanas, [[Thoma Kikis]]
|founder =
|location = [[West Hills, New York]]
|location = [[Doylestown, Pennsylvania]]
|area_served =
|area_served =
|industry = [[Pharmaceutical industry|Pharmaceutical]]
|industry = [[Pharmaceutical industry|Pharmaceutical]]
Line 18: Line 19:
[[File:US-patent-6630507.pdf|thumb|right|KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent {{patent|US|6630507}} “Cannabinoids as Antioxidants and Neuroprotectants."]]
[[File:US-patent-6630507.pdf|thumb|right|KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent {{patent|US|6630507}} “Cannabinoids as Antioxidants and Neuroprotectants."]]


'''KannaLife Sciences Inc.''' is a bio-pharmaceutical and phyto-medical company based in West Hills, NY and [[Doylestown]], [[Pennsylvania|PA]]. KannaLife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.
'''Kannalife Sciences Inc.''' , a subsidiary of [[Neuropathix|Neuropathix, Inc.]], is a bio-pharmaceutical and phyto-medical company based in [[Doylestown, Pennsylvania]] founded by Dean Petkanas and [[Thoma Kikis]].<ref>{{cite web |url=https://news.vice.com/article/the-nfls-anti-weed-policy-even-extends-to-drugs-that-could-prevent-brain-damage |archive-url=https://web.archive.org/web/20150508055419/https://news.vice.com/article/the-nfls-anti-weed-policy-even-extends-to-drugs-that-could-prevent-brain-damage |url-status=live |archive-date=May 8, 2015 |title=The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage |last=Guion |first=Payton |date=November 12, 2014 |work=VICE News |accessdate=2014-12-12 }}</ref> Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce [[oxidative stress]], and act as immuno-modulators and neuroprotectants.<ref name="nyt1">{{cite web|url=https://www.nytimes.com/2014/11/02/nyregion/a-competition-to-get-a-medical-marijuana-license-in-new-york.html?_r=0|title=For Pot Inc., the Rush to Cash In Is Underway|last=Leland|first=John|date=October 31, 2014|work=The New York Times|accessdate=2014-10-31}}</ref>


In 2011, the company was granted an Exclusive License<ref>{{cite web|url=https://www.federalregister.gov/articles/2011/11/17/2011-29726/prospective-grant-of-exclusive-license-development-of-cannabinoids-and-cannabidiols-based |title=Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. |publisher=federalregister.gov |date= |accessdate=2011-11-17}}</ref> by [[National Institutes of Health]] – Office of Technology Transfer ([[NIH Office of Technology Transfer|NIH-OTT]]) for the Commercialization of patent {{patent|US|6630507}}, “Cannabinoids as Antioxidants and Neuroprotectants."<ref>{{cite web|url=http://www.thestreet.com/story/11609018/1/kannalife-sciences-inc-signs-exclusive-license-agreement-with-national-institutes-of-health-office-of-technology-transfer-nih-ott.html |title=KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT) |publisher=thestreet.com |date= |accessdate=2012-07-09}}</ref>
In 2011, the company was granted an Exclusive License<ref>{{cite web|url=https://www.federalregister.gov/articles/2011/11/17/2011-29726/prospective-grant-of-exclusive-license-development-of-cannabinoids-and-cannabidiols-based |title=Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. |publisher=federalregister.gov |date= |accessdate=2011-11-17}}</ref> by [[National Institutes of Health]] – Office of Technology Transfer ([[NIH Office of Technology Transfer|NIH-OTT]]) for the Commercialization of patent {{patent|US|6630507}}, “Cannabinoids as Antioxidants and Neuroprotectants."<ref>{{cite web|url=http://www.thestreet.com/story/11609018/1/kannalife-sciences-inc-signs-exclusive-license-agreement-with-national-institutes-of-health-office-of-technology-transfer-nih-ott.html |title=Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT) |publisher=thestreet.com |date= |accessdate=2012-07-09}}</ref>


KannaLife is currently conducting research and development at the [[Pennsylvania Biotechnology Center of Bucks County]]<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/kannalife-in-r-amp-d-collaboration-for-cannabinoid-based-drugs/81248179/ |title=KannaLife in R&D Collaboration for Cannabinoid-Based Drugs |publisher=Genengnews.com |date= |accessdate=2013-04-04}}</ref> in Doylestown, PA, for a target drug candidate to treat [[Hepatic Encephalopathy]], an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.
Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/kannalife-in-r-amp-d-collaboration-for-cannabinoid-based-drugs/81248179/ |title=Kannalife in R&D Collaboration for Cannabinoid-Based Drugs |publisher=Genengnews.com |date= |accessdate=2013-04-04}}</ref> in Doylestown, PA, for a target drug candidate, KLS-13019<ref name=Kinney-2016>{{cite journal|author1=William A. Kinney |author2=Mark E. McDonnell |author3=Hua Marlon Zhong |author4=Chaomin Liu |author5=Lanyi Yang |author6=Wei Ling |author7=Tao Qian |author8=Yu Chen |author9=Zhijie Cai |author10=Dean Petkanas |author11=Douglas E. Brenneman |title=Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability|journal=ACS Med. Chem. Lett.|year=2016 |volume=7 |issue=4 |pages=424–428 |doi=10.1021/acsmedchemlett.6b00009|pmid=27096053 |pmc=4834656 }}</ref> to treat [[Chemotherapy-induced peripheral neuropathy]], [[Hepatic encephalopathy]], [[Concussion|Mild Traumatic Brain Injury]] and [[Chronic traumatic encephalopathy|CTE]],<ref>{{cite web|url=https://www.foxnews.com/health/medical-marijuana-company-developing-drug-to-protect-nfl-players-brains/ |title=Medical marijuana company developing drug to protect NFL players' brains |last=Mulvihill Moran |first=Jessica |date=November 9, 2014 |work=Fox News |access-date=2014-11-09}}</ref> an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.


Kannalife was featured in [[Sports Illustrated]] article on using cannabinoids to treat [[Concussion|Concussions]] and [[chronic traumatic encephalopathy|CTE]]. <ref>{{cite magazine|url=http://www.si.com/nfl/2016/07/12/cannabis-cte-treatment-kannalife |title=How cannabis is helping one company research treatment of CTE |date=July 12, 2016|magazine=Sports Illustrated}}</ref>
==External links==
* [http://www.pabiotechbc.org/biotech/directory.htm Pennsylvania Biotechnology Center]
* [http://kannalife.com Official Website]


==References==
==References==
{{Reflist}}
{{Reflist}}


[[Category:Companies established in 2010]]
[[Category:Health care companies established in 2010]]
[[Category:Companies based in New York]]
[[Category:Health care companies based in Pennsylvania]]
[[Category:Companies based in Pennsylvania]]
[[Category:Companies based in Bucks County, Pennsylvania]]
[[Category:Pharmaceutical_companies_of_the_United_States]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:Cannabis research]]
[[Category:Cannabis research]]
[[Category:American companies established in 2010]]
[[category:2010 in cannabis]]

Latest revision as of 02:11, 10 November 2024

Kannalife Sciences Inc.
Company typePrivate (Subsidiary)
IndustryPharmaceutical
Founded2010
FoundersDean Petkanas, Thoma Kikis
HeadquartersDoylestown, Pennsylvania
Total assetsExclusive License of patent US 6630507 
Websitehttp://kannalife.com
KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent US 6630507  “Cannabinoids as Antioxidants and Neuroprotectants."

Kannalife Sciences Inc. , a subsidiary of Neuropathix, Inc., is a bio-pharmaceutical and phyto-medical company based in Doylestown, Pennsylvania founded by Dean Petkanas and Thoma Kikis.[1] Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.[2]

In 2011, the company was granted an Exclusive License[3] by National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of patent US 6630507 , “Cannabinoids as Antioxidants and Neuroprotectants."[4]

Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County[5] in Doylestown, PA, for a target drug candidate, KLS-13019[6] to treat Chemotherapy-induced peripheral neuropathy, Hepatic encephalopathy, Mild Traumatic Brain Injury and CTE,[7] an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.

Kannalife was featured in Sports Illustrated article on using cannabinoids to treat Concussions and CTE. [8]

References

[edit]
  1. ^ Guion, Payton (November 12, 2014). "The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage". VICE News. Archived from the original on May 8, 2015. Retrieved 2014-12-12.
  2. ^ Leland, John (October 31, 2014). "For Pot Inc., the Rush to Cash In Is Underway". The New York Times. Retrieved 2014-10-31.
  3. ^ "Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans". federalregister.gov. Retrieved 2011-11-17.
  4. ^ "Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT)". thestreet.com. Retrieved 2012-07-09.
  5. ^ "Kannalife in R&D Collaboration for Cannabinoid-Based Drugs". Genengnews.com. Retrieved 2013-04-04.
  6. ^ William A. Kinney; Mark E. McDonnell; Hua Marlon Zhong; Chaomin Liu; Lanyi Yang; Wei Ling; Tao Qian; Yu Chen; Zhijie Cai; Dean Petkanas; Douglas E. Brenneman (2016). "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Med. Chem. Lett. 7 (4): 424–428. doi:10.1021/acsmedchemlett.6b00009. PMC 4834656. PMID 27096053.
  7. ^ Mulvihill Moran, Jessica (November 9, 2014). "Medical marijuana company developing drug to protect NFL players' brains". Fox News. Retrieved 2014-11-09.
  8. ^ "How cannabis is helping one company research treatment of CTE". Sports Illustrated. July 12, 2016.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=KannaLife&oldid=1256470055"